查看购物车
  • Traditional Chinese
  • English
封面
市场调查报告书
商品编码
1570932

吸入药物市场、机会、成长动力、产业趋势分析与预测，2024-2032

Inhalable Drugs Market, Opportunity, Growth Drivers, Industry Trend Analysis and Forecast, 2024-2032
出版日期: | 出版商: Global Market Insights Inc. | 英文 117 Pages | 商品交期: 2-3个工作天内

价格
简介目录

吸入药物市场到2023 年价值约为334 亿美元，预计2024 年至2032 年间将以6.8% 的复合年增长率增长。到肺部），广泛用于治疗气喘、慢性阻塞性肺病（COPD）、结核病（TB）和支气管炎等呼吸系统疾病。它们的快速吸收和作用使其能够非常有效地治疗呼吸道疾病。

呼吸系统疾病的盛行率日益增加是市场成长的关键驱动力。随着气喘和慢性阻塞性肺病等疾病的发生率持续上升，对创新治疗和预防措施的需求不断增长。此外，吸入技术的进步和对呼吸系统疾病认识的提高正在推动市场扩张。

市面上依药物剂型分为气雾剂、干粉剂及喷雾剂。干粉製剂预计将大幅成长，到 2032 年将达到 218 亿美元。 DPI 也易于使用、便携，并且需要最少的给药步骤，使其适合广泛的患者，从而提高了其受欢迎程度和市场成长。

按应用，市场分为呼吸系统和非呼吸系统疾病。 2023年，呼吸系统疾病领域占据市场主导地位，贡献242亿美元。吸入药物直接向肺部提供标靶治疗，减少全身副作用并更快产生治疗效果。它们绕过消化系统的能力导致更快的吸收和更立即的反应，这对于管理急性呼吸道疾病至关重要。吸入药物还需要比口服药物更小的剂量，从而提高了其生物利用度和功效。

在分销方面，市场分为医院药房、零售药房和线上平台。到 2032 年，医院药房业务预计将达到 254 亿美元。

在美国，在製药创新、强大的医疗基础设施以及研发 (R&D) 重大投资的推动下，吸入药物市场预计到 2032 年将达到 218 亿美元。美国在先进吸入式药物输送系统的开发方面处于领先地位，透过临床试验、监管批准和改善患者治疗结果促进市场成长。

目录

第 1 章：方法与范围

第 2 章：执行摘要

第 3 章：产业洞察

  • 产业生态系统分析
  • 产业影响力
    • 成长动力
      • 呼吸道疾病盛行率增加
      • 吸入技术的进步
      • 提高认识和诊断
    • 产业陷阱与挑战
      • 开发和生产成本高
      • 副作用和安全问题
  • 成长潜力分析
  • 监管环境
  • 技术景观
    • 核心技术
    • 邻近技术
  • 未来市场趋势
  • 波特的分析
  • PESTEL分析

第 4 章：竞争格局

  • 介绍
  • 公司市占率分析
  • 公司矩阵分析
  • 主要市场参与者的竞争分析
  • 竞争定位矩阵
  • 战略仪表板

第 5 章：市场估计与预测：按药物剂型，2021 - 2032 年

  • 主要趋势
  • 气雾剂
  • 干粉配方
  • 喷

第 6 章：市场估计与预测：按应用分类，2021 - 2032

  • 主要趋势
  • 呼吸系统疾病
  • 非呼吸系统疾病

第 7 章：市场估计与预测：按配销通路，2021 - 2032 年

  • 主要趋势
  • 医院药房
  • 零售药局
  • 网路药局

第 8 章：市场估计与预测：按地区，2021 - 2032

  • 主要趋势
  • 北美洲
    • 我们
    • 加拿大
  • 欧洲
    • 德国
    • 英国
    • 法国
    • 西班牙
    • 义大利
    • 荷兰
    • 欧洲其他地区
  • 亚太地区
    • 中国
    • 日本
    • 印度
    • 澳洲
    • 韩国
    • 亚太地区其他地区
  • 拉丁美洲
    • 巴西
    • 墨西哥
    • 阿根廷
    • 拉丁美洲其他地区
  • 中东和非洲
    • 南非
    • 沙乌地阿拉伯
    • 阿联酋
    • 中东和非洲其他地区

第 9 章：公司简介

  • AstraZeneca Plc
  • C.H. Boehringer Sohn AG and Co. KG.
  • CHIESI Farmaceutici S.p.A.
  • Cipla Limited
  • GSK plc
  • MannKind Corporation
  • Merck and Co., Inc.
  • Mundipharma International.
  • Novartis AG
  • Pfizer Inc.
  • PULMATRIX, INC.
  • Philip Morris International Inc.
  • Sanofi
  • Teva Pharmaceutical Industries Ltd.
  • Viatris Inc.
简介目录
Product Code: 10744

The Inhalable Drugs Market, valued at approximately USD 33.4 billion in 2023, is expected to grow at a CAGR of 6.8% between 2024 and 2032. These drugs, delivered directly to the lungs through devices like inhalers, nebulizers, and dry powder inhalers (DPIs), are widely used for treating respiratory conditions such as asthma, chronic obstructive pulmonary disease (COPD), tuberculosis (TB), and bronchitis. Their rapid absorption and action make them highly effective in addressing respiratory diseases.

The increasing prevalence of respiratory disorders is a key driver of market growth. As the incidence of conditions like asthma and COPD continues to rise, there is a growing demand for innovative treatments and preventive measures. Additionally, advancements in inhalation technology and greater awareness of respiratory conditions are fueling market expansion.

The market is segmented by drug form into aerosol, dry powder, and spray formulations. Dry powder formulations are projected to grow significantly, reaching USD 21.8 billion by 2032. These formulations offer stability due to the absence of liquid solvents or propellants, ensuring longer shelf life and reduced waste. DPIs are also easy to use, portable, and require minimal steps for administration, making them suitable for a wide range of patients, which enhances their popularity and market growth.

By application, the market is divided into respiratory and non-respiratory diseases. In 2023, the respiratory diseases segment dominated the market, contributing USD 24.2 billion. Inhalable drugs provide targeted treatment directly to the lungs, reducing systemic side effects and delivering quicker therapeutic results. Their ability to bypass the digestive system leads to faster absorption and a more immediate response, which is crucial for managing acute respiratory conditions. Inhalable drugs also require smaller doses than oral medications, increasing their bioavailability and efficacy.

Regarding distribution, the market is segmented into hospital pharmacies, retail pharmacies, and online platforms. The hospital pharmacies segment is anticipated to reach USD 25.4 billion by 2032. These pharmacies specialize in the compounding and formulation of inhalable drugs, ensuring precise dosing and high-quality standards for safe and effective treatment.

In the U.S., the inhalable drugs market is expected to reach USD 21.8 billion by 2032, driven by pharmaceutical innovation, robust healthcare infrastructure, and significant investments in research and development (R&D). The U.S. leads in the development of advanced inhalable drug delivery systems, fostering market growth through clinical trials, regulatory approvals, and enhanced patient outcomes.

Table of Contents

Chapter 1 Methodology and Scope

  • 1.1 Market scope and definitions
  • 1.2 Research design
    • 1.2.1 Research approach
    • 1.2.2 Data collection methods
  • 1.3 Base estimates and calculations
    • 1.3.1 Base year calculation
    • 1.3.2 Key trends for market estimation
  • 1.4 Forecast model
  • 1.5 Primary research and validation
    • 1.5.1 Primary sources
    • 1.5.2 Data mining sources

Chapter 2 Executive Summary

  • 2.1 Industry 360° synopsis

Chapter 3 Industry Insights

  • 3.1 Industry ecosystem analysis
  • 3.2 Industry impact forces
    • 3.2.1 Growth drivers
      • 3.2.1.1 Increasing prevalence of respiratory diseases
      • 3.2.1.2 Advancements in inhalation technology
      • 3.2.1.3 Growing awareness and diagnosis
    • 3.2.2 Industry pitfalls and challenges
      • 3.2.2.1 High development and production costs
      • 3.2.2.2 Side effects and safety concerns
  • 3.3 Growth potential analysis
  • 3.4 Regulatory landscape
  • 3.5 Technological landscape
    • 3.5.1 Core technologies
    • 3.5.2 Adjacent technologies
  • 3.6 Future market trends
  • 3.7 Porter's analysis
  • 3.8 PESTEL analysis

Chapter 4 Competitive Landscape, 2023

  • 4.1 Introduction
  • 4.2 Company market share analysis
  • 4.3 Company matrix analysis
  • 4.4 Competitive analysis of major market players
  • 4.5 Competitive positioning matrix
  • 4.6 Strategy dashboard

Chapter 5 Market Estimates and Forecast, By Drug Form, 2021 - 2032 ($ Mn)

  • 5.1 Key trends
  • 5.2 Aerosol
  • 5.3 Dry powder formulation
  • 5.4 Spray

Chapter 6 Market Estimates and Forecast, By Application, 2021 - 2032 ($ Mn)

  • 6.1 Key trends
  • 6.2 Respiratory diseases
  • 6.3 Non-respiratory diseases

Chapter 7 Market Estimates and Forecast, By Distribution Channel, 2021 - 2032 ($ Mn)

  • 7.1 Key trends
  • 7.2 Hospital pharmacies
  • 7.3 Retail pharmacies
  • 7.4 Online pharmacies

Chapter 8 Market Estimates and Forecast, By Region, 2021 - 2032 ($ Mn)

  • 8.1 Key trends
  • 8.2 North America
    • 8.2.1 U.S.
    • 8.2.2 Canada
  • 8.3 Europe
    • 8.3.1 Germany
    • 8.3.2 UK
    • 8.3.3 France
    • 8.3.4 Spain
    • 8.3.5 Italy
    • 8.3.6 Netherlands
    • 8.3.7 Rest of Europe
  • 8.4 Asia Pacific
    • 8.4.1 China
    • 8.4.2 Japan
    • 8.4.3 India
    • 8.4.4 Australia
    • 8.4.5 South Korea
    • 8.4.6 Rest of Asia Pacific
  • 8.5 Latin America
    • 8.5.1 Brazil
    • 8.5.2 Mexico
    • 8.5.3 Argentina
    • 8.5.4 Rest of Latin America
  • 8.6 Middle East and Africa
    • 8.6.1 South Africa
    • 8.6.2 Saudi Arabia
    • 8.6.3 UAE
    • 8.6.4 Rest of Middle East and Africa

Chapter 9 Company Profiles

  • 9.1 AstraZeneca Plc
  • 9.2 C.H. Boehringer Sohn AG and Co. KG.
  • 9.3 CHIESI Farmaceutici S.p.A.
  • 9.4 Cipla Limited
  • 9.5 GSK plc
  • 9.6 MannKind Corporation
  • 9.7 Merck and Co., Inc.
  • 9.8 Mundipharma International.
  • 9.9 Novartis AG
  • 9.10 Pfizer Inc.
  • 9.11 PULMATRIX, INC.
  • 9.12 Philip Morris International Inc.
  • 9.13 Sanofi
  • 9.14 Teva Pharmaceutical Industries Ltd.
  • 9.15 Viatris Inc.